Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

NCT04021082 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.

NCT NCT04021082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04021082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Lead sponsor
Portola Pharmaceuticals
Phase
Phase 2/3
Overall status
Withdrawn
Start date
November 15, 2019
Completion date
June 1, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aitl, alcl, eatl i,ii, follicular t-cell lymphoma (ftcl), hstcl, meitl, eatl type ii, nasal lymphoma, nodal lymphomas of t follicular helper (tfh), peripheral t-cell lymphoma (ptcl nos)